Position in MGNX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$62,135
+$13,481 QoQ
Shares Held
21,500
-28.9% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MGNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rangeley Capital, LLC holds $30,530,243 across 39 Biotechnology names. MGNX ranks #37 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
66,700 | $6,486,575 | |
| 2 | PRTA |
Prothena Corp Public Ltd Co
|
449,460 | $4,368,751 | |
| 3 | ARVN |
Arvinas, Inc.
|
223,990 | $2,374,294 | |
| 4 | ABUS |
Arbutus Biopharma Corp
|
500,000 | $2,250,000 | |
| 5 | KZR |
Kezar Life Sciences, Inc.
|
243,073 | $1,803,601 | |
| 6 | JANX |
Janux Therapeutics, Inc.
|
122,500 | $1,702,750 | |
| 7 | TBPH |
Theravance Biopharma, Inc.
|
103,000 | $1,671,690 | |
| 8 | BCYC |
Bicycle Therapeutics PLC
|
232,260 | $1,077,686 |
All Filings in MGNX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $62,135 | 21,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $48,654 | 30,220 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $50,769 | 30,220 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $32,670 | 27,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||